Tosilato de valemetostat (DS-3201b), un potenciador del homólogo de Zeste (EZH) 1/2 inhibidor dual, para el linfoma periférico de células T en recaída/refractario (VALENTINE-PTCL01)
Estudio de fase 2 de un solo grupo de monoterapia con tosilato de valemetostat en sujetos con linfoma periférico de células T en recaída o refractario (VALENTINE-PTCL01)
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This study was designed to evaluate the efficacy and safety of valemetostat tosylate monotherapy. The primary objective will evaluate objective response rate of valemetostat tosylate monotherapy as measured by blinded independent central review (BICR) in relapsed/refractory peripheral T-cell lymphoma.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Halle, Alemania, 06120
- Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV
-
-
-
-
-
Richmond, Australia, 3121
- Epworth Healthcare
-
-
-
-
-
Ottawa, Canadá, K1H 8L6
- Ottawa Hospital Research Institute
-
Toronto, Canadá, M5G 1Z5
- University Health Network Princess Margaret Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 4E6
- BC Cancer - Vancouver Centre
-
-
-
-
-
Seoul, Corea del Sur, 06591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul, Corea del Sur, 03080
- Seoul National University Hospital - Department of Internal
-
Seoul, Corea del Sur, 05505
- Asan Medical Center - Oncology
-
Seoul, Corea del Sur, 06351
- Samsung Medical Center - Hematology-Oncology
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Corea del Sur, 03722
- Severance Hospital, Yonsei University Health System
-
-
-
-
-
Barcelona, España, 08029
- ICO Hospital Duran i Reynals
-
Barcelona, España, 08035
- Hospital Universitario Vall d'Hebrón
-
Madrid, España, 28040
- Hospital Universitario Fundación Jiménez Díaz
-
Madrid, España, 28046
- Hospital Universitario La Paz
-
Seville, España, 41013
- Hospital Universitario Virgen del Rocio
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010
- City Of Hope National Medical Center
-
Palo Alto, California, Estados Unidos, 94304
- Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY
-
San Francisco, California, Estados Unidos, 94143
- University of California San Francisco
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University Of Colorado Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University Hospital - Winship Cancer Institute
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University - Feinberg School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Dana Farber Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55901
- Mayo Clinic - Rochester
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Hackensack University Medical Center - John Theurer Cancer Center
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Weill Cornell Medicine
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan-Kettering Cancer Center at Memorial Hospital
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Duke Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania Perelman Center for Advanced Medicine
-
-
-
-
-
Dijon, Francia, 21079
- CHU de Dijon
-
Lille, Francia, 59037
- CHRU de Lille - Hôpital Claude Huriez - Maladies du Sang
-
Lyon, Francia, 69008
- Centre Lyon Berard - Medical Oncology
-
Paris, Francia, 75010
- APHP - Hopital Saint Louis
-
Paris, Francia, 75015
- Hôpital Necker
-
Pierre-Bénite, Francia, 69495
- Centre Hospitalier Lyon Sud - Hématologie
-
Toulouse, Francia, 31100
- Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)
-
-
-
-
-
Bergamo, Italia, 24127
- ASST Papa Giovanni XXIII - Medicina Trasfusionale ed Ematologia - Bergamo
-
Bologna, Italia, 40138
- A.O.di Bologna Policl.S.Orsola
-
Monza, Italia, 20900
- PO San Gerardo, ASST Monza
-
Naples, Italia, 80131
- Fondazione Pascale, IRCCS, Istituto Nazionale dei Tumori
-
Perugia, Italia, 06132
- Ospedale S.Maria della Misericordia, AO di Perugia, Università degli Studi di Perugia
-
-
-
-
-
Fukuoka, Japón, 812-0054
- Kyushu University Hospital
-
Kagoshima, Japón, 890-8520
- Kagoshima University Hospital
-
Kyoto, Japón, 602-8566
- University Hospital - Kyoto Prefectural University of Medicine
-
Nagasaki, Japón, 852-8501
- Nagasaki University Hospital
-
Okayama, Japón, 700-8558
- Okayama University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japón, 467-8602
- Nagoya City University Hospital
-
Nagoya, Aichi-ken, Japón, 460-0001
- National Hospital Organization Nagoya Medical Center - Hematology
-
-
Chiba
-
Kashiwa, Chiba, Japón, 277-8577
- National Cancer Center Hospital East
-
-
Hokkaido
-
Sapporo, Hokkaido, Japón, 060-8648
- Hokkaido University Hospital - Medical Oncology Center
-
-
Tokyo
-
Chuo Ku, Tokyo, Japón, 104-0045
- National Cancer Center Hospital
-
-
-
-
-
Leiden, Países Bajos, 2333ZA
- Leids Universitair Medisch Centrum (LUMC) (Leiden University Medical Center)
-
Maastricht, Países Bajos, 6229 HX
- Universiteit Maastricht Academisch Ziekenhuis Maastricht
-
-
-
-
-
London, Reino Unido, NW1 2PG
- University College London Hospital
-
Nottingham, Reino Unido, NG5 1PB
- Nottingham City Hospital - Clinical Haematology
-
Oxford, Reino Unido, OX3 7LE
- Churchill Hospital
-
-
-
-
-
Kaohsiung City, Taiwán, 83301
- Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology
-
Tainan, Taiwán, 70403
- National Cheng Kung University Hospital - Internal Medicine
-
Taipei, Taiwán, 10002
- National Taiwan University Hospital - Hematology And Oncology
-
Taoyuan City, Taiwán, 33305
- Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital - Hematology and Oncology - Hematology and Oncology
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Written informed consent
-
Participants ≥18 years of age or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed.
-
Eastern Cooperative Oncology Group performance status of 0, 1, or 2
-
Cohort 1 relapsed/refractory peripheral T-cell lymphoma (PTCL):
-
Diagnosis should be confirmed by the local pathologist; local histological diagnosis will be used for eligibility determination. Participants with the following subtypes of PTCL are eligible according to 2016 WHO classification prior to the initiation of study drug. Any T-cell lymphoid malignancies not listed are excluded. Eligible subtypes include:
- Enteropathy-associated T-cell lymphoma
- Monomorphic epitheliotropic intestinal T-cell lymphoma
- Hepatosplenic T-cell lymphoma
- Primary cutaneous γδ T-cell lymphoma
- Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
- PTCL, not otherwise specified
- Angioimmunoblastic T-cell lymphoma
- Follicular T-cell lymphoma
- Nodal PTCL with T-follicular helper (TFH) phenotype
- Anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK) positive
- ALCL, ALK negative
-
-
Cohort 2 relapsed/refractory adult T-cell leukemia/lymphoma (ATL) acute, lymphoma, or unfavorable chronic type. Relapsed/refractory ATL should be confirmed by the local pathologist; local diagnosis will be used for eligibility determination. The positivity of anti-human T-cell leukemia virus type 1 (HTLV-1) antibody will be locally determined for eligibility.
-
Must have at least one lesion which is measurable in 2 perpendicular dimensions on computed tomography (or magnetic resonance imaging) based on local radiological read
-
Documented refractory, relapsed, or progressive disease after at least 1 prior line of systemic therapy.
-
Refractory is defined as:
- Failure to achieve complete response (CR) (or uncertified CR [CRu] for ATL) after first-line therapy
- Failure to reach at least partial response (PR) after second-line therapy or beyond
-
-
Must have at least 1 prior line of systemic therapy for PTCL or ATL.
- Participants must be considered hematopoietic cell transplantation (HCT) ineligible during screening due to disease status (active disease), comorbidities, or other factors; the reason for HCT ineligibility must be clearly documented.
- In the PTCL cohort, participants with ALCL must have prior brentuximab vedotin treatment.
Exclusion Criteria:
Participants meeting any exclusion criteria for this study will be excluded from this study. Below is a list of the key exclusion criteria:
-
Diagnosis of mycosis fungoides, Sézary syndrome and primary cutaneous ALCL, and systemic dissemination of primary cutaneous ALCL
-
Diagnosis of precursor T-cell leukemia and lymphoma (T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma), T-cell prolymphocytic leukemia, or T-cell large granular lymphocytic leukemia
-
Prior malignancy active within the previous 2 years except for locally curable cancer that is currently considered as cured, such as cutaneous basal or squamous cell carcinoma, superficial bladder cancer, or cervical carcinoma in situ, or an incidental histological finding of prostate cancer.
-
Presence of active central nervous system involvement of lymphoma
-
History of autologous HCT within 60 days prior to the first dose of study drug
-
History of allogeneic HCT within 90 days prior to the first dose of study drug
-
Clinically significant graft-versus-host disease (GVHD) or GVHD requiring systemic immunosuppressive prophylaxis or treatment
-
Inadequate washout period from prior lymphoma-directed therapy before enrollment, defined as follows:
- Prior systemic therapy (eg, chemotherapy, immunomodulatory therapy, or monoclonal antibody therapy) within 3 weeks prior or 5 half-lives of the drug, whichever is longer, to the first dose of study drug
- Had curative radiation therapy or major surgery within 4 weeks or palliative radiation therapy within 2 weeks prior to the first dose of study drug
-
Uncontrolled or significant cardiovascular disease, including:
- Evidence of prolongation of QT/QTc interval (eg, repeated episodes of QT corrected for heart rate using Fridericia's method >450 ms) (average of triplicate determinations)
- Diagnosed or suspected long QT syndrome or known family history of long QT syndrome
- History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes
- Uncontrolled arrhythmia (subjects with asymptomatic, controllable atrial fibrillation may be enrolled) or asymptomatic persistent ventricular tachycardia
- Participant has clinically relevant bradycardia of <50 bpm, unless the participant has a pacemaker
- History of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers within 6 months prior to Screening
- Myocardial infarction within 6 months prior to Screening
- Angioplasty or stent craft implantation within 6 months prior to Screening
- Uncontrolled angina pectoris within 6 months prior to Screening
- New York Heart Association Class 3 or 4 congestive heart failure
- Coronary/peripheral artery bypass graft within 6 months prior to Screening
- Uncontrolled hypertension (resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg)
- Complete left bundle branch block
-
History of treatment with other EZH inhibitors
-
Current use of moderate or strong cytochrome P450 (CYP)3A inducers
-
Systemic treatment with corticosteroids (>10 mg daily prednisone equivalents). Note: Short-course systemic corticosteroids (eg, prevention/treatment for transfusion reaction) or use for a non-cancer indication (eg, adrenal replacement) is permissible.
-
Known or suspected hypersensitivity to valemetostat tosylate or any of the excipients
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma
Participants who will receive 200 mg/day valemetostat tosylate and had an eligible peripheral T-cell lymphoma subtype that was confirmed by independent hematopathology central review. |
Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
Otros nombres:
|
|
Experimental: Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma
Participants who will receive 200 mg/day valemetostat tosylate and had an eligible adult T-cell leukemia/lymphoma subtype that was confirmed by the local pathologist/investigators and by documented positive anti-human T-cell leukemia virus type 1 (HTLV-1) antibody. |
Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants With Objective Response As Assessed by Blinded Independent Central Review After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)
Periodo de tiempo: From baseline until disease progression or death (whichever occurs first), up to approximately 23 months
|
For the relapsed/refractory peripheral T-cell lymphoma (PTCL) cohort, objective response rate (ORR) is defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), assessed by blinded independent central review (BICR), among participants with centrally confirmed PTCL eligible histology. |
From baseline until disease progression or death (whichever occurs first), up to approximately 23 months
|
|
Number of Participants With Treatment-emergent Adverse Events After Administration of Valemetostat Tosylate Monotherapy (Cohort 2)
Periodo de tiempo: From the time the informed consent form is signed up to 30 days after last dose, up to 23 months
|
Treatment-emergent adverse events (TEAEs) were defined as new AEs or pre-existing conditions that worsen in National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade after the first dose of study drug and up to 30 days after the last dose of study drug. |
From the time the informed consent form is signed up to 30 days after last dose, up to 23 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Número de participantes con eventos adversos surgidos del tratamiento después de la administración de monoterapia con tosilato de valemetostat (cohorte 1)
Periodo de tiempo: Desde el momento en que se firma el formulario de consentimiento informado hasta 30 días después de la última dosis
|
Desde el momento en que se firma el formulario de consentimiento informado hasta 30 días después de la última dosis
|
|
|
Plasma Concentrations of DS-3201a and CALZ-1809a After Administration of Valemetostat Tosylate Monotherapy
Periodo de tiempo: Cycle 1 Day 1, 8, 15 Predose; Cycle 1 Day 1 (1, 2, 4, 5 hours Postdose); Cycle 2 Day 1 Predose; Cycle 3 Day 1 to Cycle 5 Day 1 Predose (each cycle is 28 days)
|
Total and unbound DS-3201a (free form of valemetostat tosylate) and total CALZ-1809a (major metabolite) concentration in plasma will be assessed. |
Cycle 1 Day 1, 8, 15 Predose; Cycle 1 Day 1 (1, 2, 4, 5 hours Postdose); Cycle 2 Day 1 Predose; Cycle 3 Day 1 to Cycle 5 Day 1 Predose (each cycle is 28 days)
|
|
Duration of Response After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)
Periodo de tiempo: Time from the date of first documented response (CR or PR) until documented disease progression (progressive or relapsed disease) based on BICR assessments or death from any cause (whichever occurs first), up to approximately 56 months
|
Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (CR or PR) to the date of the first documentation of disease progression (progressive or relapsed disease) based on BICR assessments or to death due to any cause, whichever occurs first. |
Time from the date of first documented response (CR or PR) until documented disease progression (progressive or relapsed disease) based on BICR assessments or death from any cause (whichever occurs first), up to approximately 56 months
|
|
Percentage of Participants With Complete Response After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)
Periodo de tiempo: From baseline to date of first documented objective response of CR, up to approximately 56 months
|
Complete response rate is the percentage of participants achieving CR as the BOR based on BICR assessments. |
From baseline to date of first documented objective response of CR, up to approximately 56 months
|
|
Duration of Complete Response After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)
Periodo de tiempo: Time from the date of first documented CR until documented disease progression (progressive or relapsed disease) based on BICR assessments or death from any cause (whichever occurs first), up to approximately 56 months
|
Duration of complete response is defined as the time from the date of the first documentation of CR to the date of the first documentation of disease progression (progressive or relapsed disease) based on BICR assessments or to death due to any cause, whichever occurs first. |
Time from the date of first documented CR until documented disease progression (progressive or relapsed disease) based on BICR assessments or death from any cause (whichever occurs first), up to approximately 56 months
|
|
Percentage of Participants With Partial Response After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)
Periodo de tiempo: From baseline to date of first documented objective response of PR, up to approximately 56 months
|
Partial response rate is the percentage of participants achieving PR as the BOR based on BICR assessment. |
From baseline to date of first documented objective response of PR, up to approximately 56 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Global Clinical Leader, Daiichi Sankyo
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Linfoma
- Leucemia Linfoide
- Leucemia
- Linfoma de células T
- Leucemia-linfoma linfoblástico de células precursoras
- Enfermedades hemic y linfáticas
- Linfoma De Células T Periférico
- Leucemia-linfoma linfoblástico de células T precursoras
Otros números de identificación del estudio
Otros números de identificación del estudio
- DS3201-A-U202
- 2020-004954-31 (Número EudraCT)
- 2023 (Subvención/contrato del NIH de EE. UU.)
- jRCT2071200095 (Otro identificador: jRCT)
- 2023-507381-13-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Marco de tiempo para compartir IPD
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Criterios de acceso compartido de IPD
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .